© The Financial Times Ltd 2016 FT and 'Financial Times' are trademarks of The Financial Times Ltd.
As of Apr 29, 2016, the consensus forecast amongst 3 polled investment analysts covering CTI BioPharma Corp advises investors to hold their position in the company. This has been the consensus forecast since the sentiment of investment analysts deteriorated on Feb 10, 2016. The previous consensus forecast advised that CTI BioPharma Corp would outperform the market.
|Last year||3 months ago||2 months ago||4 weeks ago||Latest|
The 3 analysts offering 12 month price targets for CTI BioPharma Corp have a median target of 0.75, with a high estimate of 5.00 and a low estimate of 0.00. The median estimate represents a 47.78% increase from the last price of 0.5075. View Full Financials
Dividend information is not available for CTi Biopharma Corp. View Full Financials
On Feb 16, 2016, CTI BioPharma Corp reported 4th quarter 2015 losses of -0.13 per share. This result under-performed the -0.12 loss expectation of the 3 analysts following the company but under-performed last year's 4th quarter results by 7.14 %.
The next earnings announcement is expected on May 04, 2016. View Full Interim Financials
|Average growth rate||0.00%|
CTI BioPharma Corp reported annual 2015 losses of -0.65 per share on Feb 16, 2016. View Full Annual Financials
|Average growth rate||+19.02 %|
CTI BioPharma Corp. had 4th quarter 2015 revenues of 11.32m. This missed the 16.77m consensus estimate of the 3 analysts following the company. This was 36.34 % below the prior year's 4th quarter results. View Full Interim Financials
|Average growth rate||+229.50 %|
CTI BioPharma Corp. had revenues for the full year 2015 of 16.12m. This was 73.17 % below the prior year's results. View Full Annual Financials
|Average growth rate||+807.69 %|